Globus Pallidus Neurons In Corticobasal Degeneration is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The globus pallidus (GP), particularly the internal segment (GPi), is significantly affected in Corticobasal Degeneration (CBD). As a major output nucleus of the basal ganglia, pallidal degeneration contributes to the movement disorder phenotype, including rigidity, dystonia, and bradykinesia.
¶ Location and Structure
- Position: Lenticular nucleus, lateral to the internal capsule
- Segments:
- External segment (GPe): Indirect pathway
- Internal segment (GPi): Direct output to thalamus
- Neuronal types: GABAergic projection neurons
- Inputs: Striatum (via striatopallidal projections), subthalamic nucleus (STN), cortex
- Outputs: GPi → thalamus (ventrolateral nucleus), STN, brainstem
- Modulation: Dopaminergic inputs from substantia nigra pars compacta
- Neuronal loss: Variable, often less severe than in PSP
- Tau pathology: 4R-tau positive inclusions
- Gliosis: Reactive astrocytosis
- Pallor: Reduced myelin staining
- Coiled bodies: Oligodendroglial tau inclusions
- Neuronal inclusions: Neurofibrillary tangles
- Astrocytic plaques: Characteristic astrocyte pathology
- Thread-like processes: Tau in neuronal processes
- Increased inhibition: Enhanced GPi output to thalamus
- Thalamic suppression: Reduced thalamocortical excitation
- Net effect: Bradykinesia and rigidity
- Direct pathway: Variable involvement
- Indirect pathway: May be affected
- Network imbalance: Variable pattern
- Rigidity: Axial and limb rigidity
- Bradykinesia: Slowed movements
- Dystonia: Postural deformities
- Myoclonus: Cortical origin
- Cognitive impairment: Executive dysfunction
- Language deficits: Non-fluent aphasia
- Behavioral changes: Apathy, disinhibition
- 4R-tau accumulation: Isoform-specific pathology
- Aggregation: Filament formation
- Axonal transport disruption: Microtubule dysfunction
- Synaptic pathology: Pre-synaptic tau
- STN overactivity: Excessive excitatory input
- Glutamate dysregulation: Pathological signaling
- Calcium influx: NMDA receptor activation
- Microglial activation: Chronic inflammation
- Astrocytic response: Reactive astrocytes
- Cytokine release: Pro-inflammatory mediators
- Lewy body pathology
- GPi overactivity (in untreated PD)
- Different treatment response
- More severe GP degeneration
- 4R-tau pathology (similar)
- Different clinical phenotype
- Levodopa: Limited benefit in CBD
- Anticholinergics: May help rigidity
- Muscle relaxants: For dystonia
- Myoclonus treatment: Clonazepam
- Deep brain stimulation: GPi or STN target
- Variable outcomes: Less predictable than in PD
- Physical therapy: Maintain mobility
- Occupational therapy: Daily activities
- Speech therapy: Communication
The study of Globus Pallidus Neurons In Corticobasal Degeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503. PMID: 23359374.
-
Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011;7(5):263-272. PMID: 21458321.
-
Lee SE, Rabinovici GD, Mayo MC, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327-340. PMID: 21823156.
-
Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration: a clinical study of 36 cases. Brain. 1994;117(Pt 5):1183-1196. PMID: 7953595.
-
Eidelberg D, Takeda S, Bhattacharjee A, et al. Metabolic networks underlying corticobasal degeneration. J Cereb Blood Flow Metab. 1995;15:S214. PMID: 8548576.
-
Boxerman JL, Rogowska J, Huang Y, et al. Temporal changes in cerebral glucose metabolism in corticobasal degeneration. J Neuroimaging. 1995;5(4):211-214. PMID: 8706218.
-
Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration. J Neurol Neurosurg Psychiatry. 1998;65(4):586-595. PMID: 9771791.
-
Cotterman M, Kalia LV. Unusual parkinsonian syndromes. Continuum (Minneap Minn). 2021;27(5):1320-1342. PMID: 34622957.